Slingshot members are tracking this event:
AbbVie and Roche's venetoclax gets new Breakthrough Therapy tag for blood cancer
Do you think this event is important to the companies below? How will it affect their stock price?
The designation is supported by an investigational study of venetoclax in combination with rituximab in patients with R/R CLL. Rituximab is indicated in combination with fludarabine and cyclophosphamide for the treatment of patients with previously untreated and previously treated CD20-positive CLL. Rituximab in combination with the investigational agent venetoclax is not approved for the treatment of R/R CLL.
In April 2015, the FDA granted Breakthrough Therapy Designation to single agent venetoclax for the treatment of CLL in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation. According to the FDA, Breakthrough Therapy Designation is intended to expedite the development and review of therapies for serious or life-threatening conditions. In January, AbbVie announced that the FDA granted priority review for the single agent NDA application.
Slingshot Insights Explained
Jan 20, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Venetoclax, Breakthrough Therapy Designation, Blood Cancer, Rituximab, Combination, Refractory Chronic Lymphocytic Leukemia